No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for MapLight Therapeutics, Inc. (MPLT) stock was $9.69 as of Oct 6, 2026, 4:00 PM EDT, up 4.47% from the previous close.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders.
Biotechnology · Redwood City, CA
Next Earnings Date
Dec 3, 2026
58 days away
EPS Estimate
-1.18
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.32
vs Estimate
$-1.31
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MPLT | $411.21M | $9.69 | +4.47% | N/A | N/A | N/A | N/A |
| 2SRTA | $411.00M | $4.75 | -1.25% | -11.04% | -13.77% | N/A | vs MPLT |
| 3EIKN | $406.58M | $7.51 | -0.40% | N/A | N/A | N/A | vs MPLT |
| 4RZLT | $415.98M | $4.32 | -0.23% | -52.25% | -9.57% | -25.30% | vs MPLT |
| 5SENS | $416.27M | $9.96 | -3.39% | -8.79% | -30.89% | -18.02% | vs MPLT |
| 6AVIR | $405.74M | $5.07 | -1.17% | +76.42% | -34.44% | N/A | vs MPLT |
forward FY estimate
N/A
Consensus Rating
Based on 13 analysts
Average Price Target
$26.54
+173.9% upside
Low
$13.00
Current
$9.69
High
$43.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.35 | $-1.18 | $-1.00 | 5 |
| Quarter ending Dec 2026 | $-1.42 | $-1.18 | $-0.85 | 5 |
| Quarter ending Mar 2027 | $-1.16 | $-1.16 | $-1.16 | 3 |
| Quarter ending Jun 2027 | $-1.14 | $-1.14 | $-1.14 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.36 | $-4.94 | $-4.48 | 8 |
| FY 2027 | $-4.38 | $-3.86 | $-3.15 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $16.67M | $16.67M | $16.67M | 12 |
